| scholarly article | Q13442814 |
| P50 | author | Takashi Kanbayashi | Q89617945 |
| P2093 | author name string | Tetsuo Shimizu | |
| Yuka Sugawara Kikuchi | |||
| P2860 | cites work | Therapeutic drug monitoring of clozapine and relapse--a retrospective study of routine clinical data. | Q30765869 |
| Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients | Q34288360 | ||
| Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance | Q35802661 | ||
| Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia | Q36024542 | ||
| Effect of caffeine on clozapine pharmacokinetics in healthy volunteers | Q36055008 | ||
| Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method | Q36094183 | ||
| Sex differences in plasma clozapine and norclozapine concentrations in clinical practice and in relation to body mass index and plasma glucose concentrations: a retrospective survey | Q36294225 | ||
| Electroencephalographic abnormalities in clozapine-treated patients: a cross-sectional study | Q39995056 | ||
| The usefulness of monitored therapy using Clozapine concentration in the blood serum for determining drug dose in Polish schizophrenic patients. | Q40597170 | ||
| Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients | Q40779000 | ||
| Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine | Q41093298 | ||
| Clozapine-induced seizures and EEG changes | Q42282305 | ||
| EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients | Q42289198 | ||
| Clozapine-induced electroencephalogram changes as a function of clozapine serum levels | Q42548854 | ||
| Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection | Q43794493 | ||
| EEG abnormalities during treatment with typical and atypical antipsychotics | Q43843047 | ||
| Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine | Q43974558 | ||
| Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables | Q43986056 | ||
| Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy | Q44594935 | ||
| An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels | Q46423766 | ||
| Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. | Q46592286 | ||
| Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients | Q47599108 | ||
| Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients | Q47740544 | ||
| Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients | Q49646975 | ||
| Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. | Q50859607 | ||
| Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. | Q51012886 | ||
| Influence of patient-related variables on clozapine plasma levels. | Q52055220 | ||
| Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age | Q69795312 | ||
| EEG alterations in patients treated with clozapine in relation to plasma levels | Q72521614 | ||
| Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients | Q73101138 | ||
| Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients | Q73296823 | ||
| Clozapine dosages and plasma drug concentrations | Q73681688 | ||
| Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study | Q74212194 | ||
| Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia | Q85299028 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| Treatment-resistant schizophrenia | Q60491684 | ||
| serum concentration | Q126107668 | ||
| P304 | page(s) | 279-284 | |
| P577 | publication date | 2018-04-01 | |
| P1433 | published in | Psychiatry investigation | Q26853796 |
| P1476 | title | Relationship between Clozapine-Induced Electroencephalogram Abnormalities and Serum Concentration of Clozapine in Japanese Patients with Treatment-Resistant Schizophrenia | |
| P478 | volume | 16 |
Search more.